updated 3/28/2011 7:17:16 AM ET 2011-03-28T11:17:16

DALLAS, March 28, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Biostar Pharmaceuticals Inc. (Nasdaq:BSPM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/BSPM

Biostar Pharmaceuticals Inc. (BSPM), through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic hepatitis B, a disease affecting nearly 10% of the Chinese population. In addition to its hepatitis product, BSPM currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements. As of December 31, 2010, BSPM has expanded its rural supply network to over 10,000 sales outlets in 22 provinces. Sales to rural areas increased approximately 95% to $14.2 million during the twelve months ended 2010, representing 18% of total sales.

This newsletter has been helping traders make great investment decisions on BSPM; click here for a 25% discount offer.

In the report, the analyst notes:

"BSPM shares gained 36 cents, or 16.22%, on Friday after the Company reported strong fourth quarter and full-year results that impressed investors. The Company said its quarterly profit rose to $6.1 million, or 22 cents a share, compared with $1.7 million, or 7 cents a share, during the same period a year ago."

"BSPM reported that sales of its over-the-counter hepatitis B treatment Xin Aoxing capsules rose nearly 57% from the year-ago quarter to $18.6 million, with a gross margin of 87.0%. It said the order rate for the drug, which represented almost two thirds of total fourth quarter 2010 revenues, started to rebound at the end of the third quarter and continued to accelerate through the fourth quarter."

To read the entire report visit: www.microstockprofit.com/lp/BSPM

See what investors are saying about BSPM at http://www.stockhideout.com

Get breaking news on BSPM at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.66%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.21%
Cash Back Cards 17.73%
17.70%
Rewards Cards 17.00%
16.96%
Source: Bankrate.com